PI3Kγδ inhibition suppresses key disease features in a rat model of asthma.

Autor: Pinkerton JW; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.; Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK., Preite S; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden., Piras A; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden., Zervas D; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.; Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK., Markou T; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.; Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK., Freeman MS; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.; Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK., Hofving T; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden., Ivarsson E; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden., Bonvini SJ; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.; Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK., Brailsford W; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden., Yrlid L; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden., Belvisi MG; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.; Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK., Birrell MA; Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden. mark.birrell@astrazeneca.com.; Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK. mark.birrell@astrazeneca.com.
Jazyk: angličtina
Zdroj: Respiratory research [Respir Res] 2024 Apr 23; Vol. 25 (1), pp. 175. Date of Electronic Publication: 2024 Apr 23.
DOI: 10.1186/s12931-024-02814-1
Abstrakt: Background: Two isoforms of Phosphoinositide 3-kinase (PI3K), p110γ and p110δ, are predominantly expressed in leukocytes and represent attractive therapeutic targets for the treatment of allergic asthma. The study aim was to assess the impact of administration of an inhaled PI3Kγδ inhibitor (AZD8154) in a rat model of asthma.
Methods: Firstly, we checked that the tool compound, AZD8154, inhibited rat PI3K γ & δ kinases using rat cell-based assays. Subsequently, a time-course study was conducted in a rat model of asthma to assess PI3K activity in the lung and how it is temporally associated with other key transcription pathways and asthma like features of the model. Finally, the impact on lung dosed AZD8154 on target engagement, pathway specificity, airway inflammation and lung function changes was assessed.
Results: Data showed that AZD8154 could inhibit rat PI3K γ & δ isoforms and, in a rat model of allergic asthma the PI3K pathway was activated in the lung. Intratracheal administration of AZD8154 caused a dose related suppression PI3K pathway activation (reduction in pAkt) and unlike after budesonide treatment, STAT and NF-κB pathways were not affected by AZD8154. The suppression of the PI3K pathway led to a marked inhibition of airway inflammation and reduction in changes in lung function.
Conclusion: These data show that a dual PI3Kγδ inhibitor suppress key features of disease in a rat model of asthma to a similar degree as budesonide and indicate that dual PI3Kγδ inhibition may be an effective treatment for people suffering from allergic asthma.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje